RVXoldtimer, I think Don has delivered what he talked about at last years AGM. Please see excerpts from the Sept 2012 AGM.

Source - AGM transcript (imtesty)

SLIDE 3

OK, here’s the share structure. We were spun out in 2013, private company, a fully reporting issuer. So we are basically a public company that just doesn’t trade yet. It’s been hard to imagine being a trading company yet because we needed certain aspects to happen before we can move onto the market. If I’d moved this company onto the market last year, the first thing pretty much everybody in this room would have done was sold half your shares. So we need some really good momentum points, and I think we have those now, so we’re looking forward to the status here.

So we have now raised over 50 million dollars. There is more to come shortly. We’re working on some licensing equity component, very similar to what we did with Hepalink in China and also in China. So it takes a little longer to get deals completed there, but you can expect to see something fairly quick.

Newsoara - Now with the Newsoara deal plus other PPS deals they have funding for 21 months or so.

Cash burn rate reported at the AGM was approx $0.7mm/month but with TNBC that may increase. We might see at the next AGM.

TNBC – This trial has now started and I recall a 2 to 3 year timeline on this but I could not find the presentation.

SLIDE 23

Now what wasn’t on that list is PARP inhibition

This is becoming a very popular area.

And I hope to be able to publicly inform you in the next few weeks

·       That we’re going to be involved in this area and the PARP inhibition we will be using in Triple negative breast cancer.

It is a very aggressive deadly type of breast cancer

So it looks like there is promise enough for the joint trial on TNBC with Pfizer and an investment from Newsoara. Time to settle in for the long hall and hope that some trigger like success on the BoM trial may lend enough credibility to the RVX and Zenith platforms to trigger a CVR or buyout.

GLTA

Toinv